Chronic Hepatitis B Therapeutics Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report

Published: November 28, 2025 Report Code: GDHC333PIDR-7M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

The report provides an in-depth assessment of the CHB therapeutics market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.

The hepatitis B virus (HBV) is a member of the Orthohepadnavirus genus, from the Hepadnaviridae family. HBV is transmitted through infected blood and body fluids, most commonly through unprotected sex and contaminated needles. HBV can also be transmitted from mother to child at birth, which is particularly common within highly endemic regions. Acute hepatitis B is a short-term illness that occurs within the first six months following HBV exposure. However, if the body fails to clear the virus after six months, chronic hepatitis B (CHB) virus infection occurs. CHB is specifically defined by the presence of hepatitis B surface antigen (HBsAg) in a patient’s serum for at least six months. CHB is a lifelong disease for most patients, who are then at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC).

GlobalData forecasts the global CHB marketplace-which, for the purposes of this report, comprises seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, Japan)-to experience growth during the forecast period. This growth will be driven primarily by the highly anticipated arrival of CHB functional cures, which include GSK’s toll like receptor 8 agonist, bepirovirsen; Gilead Sciences’ toll like receptor 8 agonist, selgantolimod; Aligos Therapeutics’ capsid protein inhibitor, ALG-000184; and Arbutus Biopharma’s HBV surface antigen inhibitor, imdusiran. Nevertheless, patent expiries, generic erosion across the 7MM, and reductions in the diagnosed prevalent cases are expected to curtail market growth.

Scope

Overview of CHB including etiology, pathophysiology and epidemiology.

Key topics covered include current market landscape, strategic competitor assessment, unmet needs and opportunities, R&D trends, pipeline assessment, and current and future players.

CHB therapeutics market outlook from 2024-2034, including annual cost of therapy per patient, and total sales revenues per product for each of the 7MM.

Key Highlights

Report deliverables include a Word report and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2024-2034

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and identify the companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the 7MM CHB therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM CHB therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Gilead Sciences
Aligos Therapeutics
GSK
Arbutus Biopharma

Table of Contents

List of Tables

List of Figures

1 Chronic Hepatitis B: Executive Summary

1.1 CHB market to experience growth from 2024–34

1.2 Gilead, GSK, Aligos, and Arbutus are key future players

1.3 Functional cure drugs are expected to address a major unmet need

1.4 Late-stage pipeline drugs will be a key driver of growth

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: total prevalent cases of CHB

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CHB

4.4.5 Diagnosed prevalent cases of CHB by HBeAg status

4.4.6 Diagnosed prevalent cases of CHB by cirrhosis status

4.4.7 Diagnosed prevalent cases of CHB with cirrhosis by cirrhosis stage

4.4.8 Diagnosed prevalent cases of CHB segmented by both HBeAg and cirrhosis status

4.4.9 Treated diagnosed prevalent cases of CHB segmented by both HBeAg and cirrhosis status

4.5 Epidemiological forecast for CHB (2024–34)

4.5.1 Total prevalent cases of CHB

4.5.2 Age-specific total prevalent cases of CHB

4.5.3 Sex-specific total prevalent cases of CHB

4.5.4 Diagnosed prevalent cases of CHB

4.5.5 Age-specific diagnosed prevalent cases of CHB

4.5.6 Sex-specific diagnosed prevalent cases of CHB

4.5.7 Diagnosed prevalent cases of CHB by HBeAg status

4.5.8 Diagnosed prevalent cases of CHB by cirrhosis status

4.5.9 Diagnosed prevalent cases of CHB by cirrhosis stage

4.5.10 Diagnosed prevalent cases of CHB by HBeAg and cirrhosis status

4.5.11 Treated diagnosed prevalent cases of CHB by HBeAg and cirrhosis status

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Development of a functional cure

7.3 Increased screening

7.4 Increased linkage to care

7.5 Awareness of preventative measures

8 R&D Strategies

8.1 Overview

8.1.1 Functional cure

8.1.2 Combination therapy

8.1.3 Novel drug classes

8.2 Clinical trials design

8.2.1 Endpoints

8.2.2 Inclusion/exclusion criteria

8.2.3 Combination therapies

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Reviewers

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: Chronic hepatitis B: key metrics in the 7MM

Table 2: Phases of CHB infection

Table 3: Risk factors and comorbidities for CHB

Table 4: Treatment guidelines for chronic hepatitis B

Table 5: Top 10 deals by value, 2015–25

Table 6: CHB market – global drivers and barriers, 2024–34

Table 7: Key events impacting sales for CHB in the US, 2024–34

Table 8: CHB market – drivers and barriers in the US, 2024–34

Table 9: Key events impacting sales for CHB in the 5EU, 2024–34

Table 10: CHB market – drivers and barriers in the 5EU, 2024–34

Table 11: Key events impacting sales for CHB in Japan, 2024–34

Table 12: CHB market – drivers and barriers in Japan, 2024–34

Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Sales forecast by country for CHB in 2024 and 2034

Figure 2: Analysis of the company portfolio gap in CHB during the forecast period

Figure 3: Competitive assessment of the CHB pipeline drugs benchmarked against the SOC, Vemlidy

Figure 4: Hepatitis B virus structure

Figure 5: Key steps in HBV replication and potential therapeutic targets

Figure 6: 7MM, total prevalence of CHB, men and women, %, all ages, 2014–34

Figure 7: 7MM, diagnosed prevalence of CHB, men and women, %, all ages, 2014–34

Figure 8: 7MM, sources used to forecast the total prevalent cases of CHB

Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of CHB

Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of CHB by HBeAg status

Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of CHB with and without cirrhosis

Figure 12: 7MM, sources used to forecast the diagnosed prevalent cases of CHB by cirrhosis type

Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of CHB by both HBeAg and cirrhosis status

Figure 14: 7MM, total prevalent cases of CHB, N, both sexes, all ages, 2024

Figure 15: 7MM, total prevalent cases of CHB by age, N, both sexes, 2024

Figure 16: 7MM, total prevalent cases of CHB by sex, N, all ages, 2024

Figure 17: 7MM, diagnosed prevalent cases of CHB, N, both sexes, all ages, 2024

Figure 18: 7MM, diagnosed prevalent cases of CHB by age, N, both sexes, 2024

Figure 19: 7MM, diagnosed prevalent cases of CHB by sex, N, all ages, 2024

Figure 20: 7MM, diagnosed prevalent cases of CHB by HBeAg status, N, both sexes, all ages, 2024

Figure 21: 7MM, diagnosed prevalent cases of CHB by cirrhosis status, N, both sexes, all ages, 2024

Figure 22: 7MM, diagnosed prevalent cases of CHB with cirrhosis segmented by cirrhosis stage, N, both sexes, all ages, 2024

Figure 23: 7MM, diagnosed prevalent cases of CHB by HBeAg status and cirrhosis status, N, both sexes, all ages, 2024

Figure 24: 7MM, treated diagnosed prevalent cases of CHB by HBeAg status and cirrhosis status, N, both sexes, all ages, 2024

Figure 22: CHB treatment algorithm

Figure 26: Unmet needs and opportunities in CHB

Figure 27: Overview of the development pipeline in CHB

Figure 28: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for CHB in the 7MM during the forecast period

Figure 29: Competitive assessment of the CHB pipeline drugs benchmarked against the SOC, Vemlidy

Figure 30: Analysis of the company portfolio gap in CHB during the forecast period

Figure 31: Global (7MM) sales forecast by country for CHB in 2024 and 2034

Figure 32: Sales forecast by drug for CHB in the US in 2024 and 2034

Figure 33: Sales forecast by drug for CHB in the 5EU in 2024 and 2034

Figure 34: Sales forecast by drug for CHB in Japan in 2024 and 2034

Chronic Hepatitis B Therapeutics Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Hepatitis B Therapeutics Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

Access a live Chronic Hepatitis B Therapeutics Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Chronic Hepatitis B Therapeutics Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Scope

Key Highlights

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports